All posts by: Michael Zand

About Michael Zand

Gene Therapy MYO-101 Receives FDA’s Orphan Drug Status for LGMD2E Treatment – Muscular Dystrophy News

Continue reading

2018-04-27 NEWS

Muscular Dystrophy News

Gene Therapy MYO-101 Receives FDA’s Orphan Drug Status for LGMD2E Treatment
Muscular Dystrophy News
The U.S. Food and Drug Administration (FDA) granted orphan drug status to MYO-101, a gene therapy being developed by Myonexus Therapeutics for the treatment of limb girdle muscular dystrophy type 2E (LGMD2E) . The FDA’s orphan drug designation is

Continue reading

2018-04-27 NEWS

Quartz

After gene-editing, Crispr’s new frontier to detect diseases is closer to becoming a reality
Quartz
The world is one step closer to using Crispr, a powerful gene-editing tool, to solve one of the hardest parts of being a doctor: figuring out what is wrong with a patient. While there are a range of diagnostic tools to help doctors with that very first
CRISPR/Cas9 Silences Gene Associated with High CholesterolDuke Today
All you need to know for round 2 of the CRISPR patent fightSTAT
CRISPR at Home: Health for the Whole FamilyGenetic Engineering & Biotechnology News
Genetic Literacy Project –Futurity: Research News
all 12 news articles »
Continue reading

2018-04-27 NEWS

Xconomy

Bio Roundup: CRISPR Tests, Parkinson’s Questions, Opioid Bills & More
Xconomy
Xconomy National —. Politics is more partisan than ever these days, but the opioid crisis might be one of the few issues where elected officials find common ground. This week, members of Congress exercised a bipartisan effort in both chambers to